Studies in breast cancer have documented improved pathologic complete remission (pCR) and disease-free survival in HER2+ or triple negative breast cancer (TNBC) patients with CD8+ to Foxp3+ cell ratio (CFR) greater than 1 when assessed by immunohistochemistry [55]. This evidence concerns the gene ERBB2 and breast carcinoma.